Anzeige
Mehr »
Mittwoch, 11.02.2026 - Börsentäglich über 12.000 News
Drohnen, Robotik, E-Autos: Diese Hightech-Aktie könnte jetzt zünden
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
27 Leser
Artikel bewerten:
(0)

United States Atrial and Ventricular Septal Defect Devices Market Report 2018

DUBLIN, Jan. 9, 2018 /PRNewswire/ --

The "US Market Report for Atrial and Ventricular Septal Defect Devices 2018 - MedCore" report has been added to Research and Markets' offering.

Research and Markets Logo

VSDs are defects in the ventricular septum, the wall dividing the left and right ventricles of the heart. VSDs are similar to ASDs but tend to cause fewer complications because VSDs are small and most people with the defect barely feel the symptoms. However, approximately 10% of individuals with VSD will develop Eisenmenger's Syndrome, which is a condition that can curtail life expectancy by several years.

This condition can also be found in ASD patients. VSDs are found in approximately 3 to 3.5 of every 1,000 births but the vast majority of VSDs are likely to close spontaneously during childhood. Only in a small percentage of cases, they will have to be treated surgically. ASDs and VSDs can be treated percutaneously by inserting a device through the defect, which expands and forms a seal around the defect. Many of these devices allow heart tissue to grow over the device with time.

Atrial septal defect (ASD) and ventricular septal defect (VSD) are both conditions that involve incorrect blood flow within the heart. ASD is an opening in the muscular tissue that separates the sides of the heart's two upper chambers. Due to blood reflux, the heart is made to work more strenuously and below its optimal level.

The condition is more common in females than males and tends to get worse with time. If left untreated, ASD can cause hypertension, heart arrhythmia and even a stroke. As with patent foramen ovale (PFO), ASD can be treated with open-heart surgery, but the operation is highly invasive. ASDs are found in approximately 1 in 1,500 live births and can lead to death if not treated in some cases.

Key Topics Covered:

Executive Summary
U.S. Cardiac Surgery And Heart Valve Device Market Overview
Competitive Analysis
Market Trends
Market Developments
Procedure Numbers
Procedure Codes Investigated
Markets Included
Key Report Updates
Version History

1. Research Methodology

2. Disease Overview
2.1 Basic Anatomy
2.1.1 Coronary Artery Disease
2.1.2 Myocardial Infarction
2.1.3 Angina Pectoris
2.1.4 Heart Valve Disease
2.1.5 Congestive Heart Failure

3. Product Portfolio
3.1.1 Tissue Heart Valves
3.1.2 Mechanical Tissue Heart Valves
3.1.3 Annuloplasty Repair Devices
3.1.4 Transcatheter Aortic Valve Replacement Devices
3.1.5 Transcatheter Mitral Valve Repair Devices
3.1.6 On-Pump Coronary Artery Bypass Devices
3.1.7 Off-Pump Coronary Artery Bypass Devices
3.1.8 Endoscopic Vessel Harvesting Devices
3.1.9 Anastomosis Assist Devices
3.1.10 Transmyocardial Revascularization Devices
3.1.11 Ventricular Assist Devices
3.1.12 Intra-Aortic Balloon Pump Device
3.1.13 Temporary Artificial Heart Replacement Device
3.1.14 Remote Hemodynamic Monitoring System Devices
3.1.15 Patent Foramen Ovale Devices
3.1.16 Atrial & Ventricular Septal Defect Device
3.1.17 Left Atrial Appendage Closure Device
3.1.18 Extracorporeal Membrane Oxygenation Machine
3.2 Fda Recalls
3.2.1 Maquet
3.2.2 Medtronic
3.2.3 Heartware Inc
3.3 Clinical Trials
3.3.1 Medtronic
3.3.2 St. Jude Medical
3.3.3 Abiomed
3.3.4 Heartware Inc

4. Atrial And Ventricular Septal Defect Device Market
4.1 Introduction
4.2 Market Overview
4.3 Market Analysis And Forecast
4.3.1 Total Atrial And Ventricular Septal Defect Device Market
4.3.2 Atrial Septal Defect Device Market
4.3.3 Ventricular Septal Defect Device Market
4.4 Drivers And Limiters
4.4.1 Market Drivers
4.4.2 Market Limiters
4.5 Competitive Market Share Analysis

Companies Mentioned

  • Edwards Lifesciences
  • St. Jude Medical
  • Medtronic
  • Maquet
  • Abiomed
  • HeartWare Inc.
  • Sorin Group
  • Terumo
  • Abbott Laboratories
  • Teleflex Medical
  • Cardiac Assist
  • AtriCure
  • W.L. Gore
  • SynCardia
  • Boston Scientific
  • Cryolife
  • Berlin Heart
  • Cardica
  • Chase Medical
  • Genesee Biomedical
  • Karl Storz
  • LifeNet Health
  • Microline Surgical
  • Novadaq
  • On-X
  • Saphena Medical
  • SentreHeart
  • Vitalitec

For more information about this report visit https://www.researchandmarkets.com/research/3rf3wf/united_states?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

© 2018 PR Newswire
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.